Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction

BMC Biotechnology

Jeremy Edwards²  Eric Wickstrom¹  James Butz² 

[1]Department of Biochemistry and Molecular Pharmacology, Thomas Jefferson University, Philadelphia, PA 19107, USA

[2]Department of Chemical Engineering, University of Delaware, Newark, DE 19716, USA

关键词: loss of heterozygosity;    mutations;    K-ras2;    p53;    pancreatic cancer;    immobilized PCR;    Polony;   

Others  :  1160959
DOI  :  10.1186/1472-6750-3-11

 received in 2003-05-20, accepted in 2003-07-23,  发布年份 2003

【 摘 要 】

Background

The identification of known mutations in a cell population is important for clinical applications and basic cancer research. In this work an immobilized form of the polymerase chain reaction, referred to as polony technology, was used to detect mutations as well as gene deletions, resulting in loss of heterozygosity (LOH), in cancer cell lines. Specifically, the mutational hotspots in p53, namely codons 175, 245, 248, 249, 273, and 282, and K-ras2, codons 12, 13 and 61, were genotyped in the pancreatic cell line, Panc-1. In addition LOH analysis was also performed for these same two genes in Panc-1 by quantifying the relative gene copy number of p53 and K-ras2.

Results

Using polony technology, Panc-1 was determined to possess only one copy of p53, which possessed a mutation in codon 273, and two copies of K-ras2, one wildtype and one with a mutation in codon 12. To further demonstrate the general approach of this method, polonies were also used to detect K-ras2 mutations in the pancreatic cell lines, AsPc-1 and CAPAN-1.

Conclusions

In conclusion, we have developed an assay that can detect mutations in hotspots of p53 and K-ras2 as well as diagnose LOH in these same genes.

【 授权许可】

   
2003 Butz et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N: Enzymatic Amplification of Beta-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle-Cell Anemia. Science 1985, 230:1350-1354.
• [2]Mitra RD, Church GM: In situ localized amplification and contact replication of many individual DNA molecules. Nucleic Acids Res 1999, 27:e34.
• [3]Mitra RD, Butty VL, Shendure J, Williams BR, Housman DE, Church GM: Digital genotyping and haplotyping with polymerase colonies. Proc Natl Acad Sci U S A 2003, 100:5926-5931.
• [4]Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
• [5]Ponder BA: Cancer genetics. Nature 2001, 411:336-341.
• [6]Evan GI, Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
• [7]Fearon ER: Tumor-Suppressor Genes. In The Genetic Basis of Human Cancer. Edited by Kinzler KW and Vogelstein V. The McGrw-Hill Companies; 2002:197-206.
• [8]Kinzler KW, Vogelstein V: Introduction. In The Genetic Basis of Human Cancer. Edited by Kinzler KW and Vogelstein V. The McGraw-Hill Companies; 2002.
• [9]Park M: Oncogenes. In The Genetic Basis of Human Cancer. Edited by Kinzler KW and Vogelstein V. The McGraw-Hill Companies; 2002:177-196.
• [10]Cancer Facts & Figures 2003 Atlanta, American Cancer Society; 2003:52.
• [11]Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE: Molecular pathology of pancreatic cancer. Cancer Journal 2001, 7:251-258.
• [12]Wilentz RE, Argani P, Hruban RH: Loss of heterozygosity or intragenic mutation, which comes first? Am. J. Pathol. 2001, 158:1561-1563.
• [13]Glazko GV, Rogozin IB, Glazko VI: Mutational hotspots in the p53 gene revealed by classification analysis. Exp. Oncol. 2002, 24:32-37.
• [14]Harris CC: 1995 Deichmann Lecture - p53 tumor suppressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol. Lett. 1995, 82-3:1-7.
• [15]Yanez L, Groffen J, Valenzuela DM: C-K-Ras Mutations in Human Carcinomas Occur Preferentially in Codon-12. Oncogene 1987, 1:315-318.
• [16]Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most Human Carcinomas of the Exocrine Pancreas Contain Mutant C-K-Ras Genes. Cell 1988, 53:549-554.
• [17]Land H, Parada LF, Weinberg RA: Cellular Oncogenes and Multistep Carcinogenesis. Science 1983, 222:771-778.
• [18]Cooper GM: Cellular Transforming Genes. Science 1982, 217:801-806.
• [19]Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M, Scarpa A: Genetic profile of 22 pancreatic carcinoma cell lines - Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. Int. J. Pathol. 2001, 439:798-802.
• [20]Sun CL, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A: Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol. Rep. 2001, 8:89-92.
• [21]Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M: Comparative-Analysis of Mutations in the P53 and K-Ras Genes in Pancreatic-Cancer. Int. J. Cancer 1994, 58:185-191.
• [22]Vogelstein B, Kinzler KW: Digital PCR. Proc Natl Acad Sci U S A 1999, 96:9236-9241.
• [23]Wang Y, Yamaguchi Y, Watanabe H, Ohtsubo K, Wakabayashi T, Sawabu N: Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K-ras mutation. J. Gastroenterol. 2002, 37:831-839.
• [24]Ha A, Watanabe H, Yamaguchi Y, Ohtsubo K, Wang Y, Motoo Y, Okai T, Wakabayahi T, Sawabu N: Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma. Pancreas 2001, 23:356-363.
• [25]Queneau PE, Adessi GL, Thibault P, Cleau D, Heyd B, Mantion G, Carayon P: Early detection of pancreatic cancer in patients with chronic pancreatitis: Diagnostic utility of a K-ras point mutation in the pancreatic juice. Am. J. Gastroenterol. 2001, 96:700-704.
• [26]Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, Sninsky JJ: Detection of Ras Gene-Mutations in Pancreatic-Juice and Peripheral-Blood of Patients with Pancreatic Adenocarcinoma. Cancer Res. 1993, 53:2472-2474.
• [27]Berthelemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L: Identification of K-Ras Mutations in Pancreatic-Juice in the Early Diagnosis of Pancreatic-Cancer. Ann. Intern. Med. 1995, 123:188-191.
• [28]Lieber M, Zzetta J, Lsonrees W, Plan M, Daro G: Establishment of a Continuous Tumor-Cell Line (Panc-1) from a Human Carcinoma of Exocrine Pancreas. Int. J. Cancer 1975, 15:741-747.
• [29]Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH, Berjian R, Douglass HO, Martin EW, Chu TM: Human Pancreatic Adenocarcinoma - Invitro and Invivo Morphology of a New Tumor Line Established from Ascites. In Vitro-Journal of the Tissue Culture Association 1982, 18:24-34.
• [30]Fogh J, Wright WC, Loveless JD: Absence of Hela-Cell Contamination in 169 Cell Lines Derived from Human Tumors. J. Natl. Cancer Inst. 1977, 58:209-214.